Febuxostat, a Xanthine Oxidase Inhibitor, Decreased Macrophage Matrix Metalloproteinase Expression in Hypoxia.

Febuxostat, a Xanthine Oxidase Inhibitor, Decreased Macrophage Matrix Metalloproteinase Expression in Hypoxia.
复制标题

DOI:
10.3390/biomedicines8110470
复制
发表时间:
2020-11-03
期刊:
影响因子:
4.7
通讯作者:
Maemura K
Maemura K
中科院分区:
工程技术3区
文献类型:
--
作者:
Wei S;Isagawa T;Eguchi M;Sato D;Tsukano H;Miyata K;Oike Y;Takeda N;Ikeda S;Kawano H;Maemura K

文献摘要

参考文献

被引文献

相似文献

粥样斑块区域的巨噬细胞产生基质金属蛋白酶 (MMP) 并降低斑块稳定性。动脉粥样硬化区域动脉壁的组织氧张力降低。缺氧诱导因子(HIF)-1α在缺氧诱导基因的转录激活中发挥着关键作用。然而,HIF-1α 独立通路在缺氧反应中的确切作用尚不清楚。黄嘌呤氧化酶(XO)是一种利用分子氧并产生活性氧(ROS)的酶。在这里,我们发现源自 XO 的 ROS 增加了小鼠巨噬细胞中 MMP-3、-10 和 -13 的表达。我们发现巨噬细胞 MMP-3、-10 和 -13 的转录水平在缺氧条件下增加。缺氧诱导 HIF-1α 缺陷型巨噬细胞中 MMP 的表达。 N-乙酰半胱氨酸 (NAC) 或非布索坦(一种 XO 抑制剂)可抑制小鼠巨噬细胞中的 MMP 表达。非布索坦降低了载脂蛋白 E 缺陷小鼠斑块破裂的发生率。我们的结果表明,非布索坦通过抑制巨噬细胞 MMP-9 和 -13 的活性来稳定动脉粥样硬化斑块。非布索坦给药是治疗动脉粥样硬化患者的潜在治疗选择。
Macrophages in the atheroma region produce matrix metalloproteinases (MMPs) and decrease plaque stability. Tissue oxygen tension decreases in the arterial wall of the atherosclerotic region. Hypoxia inducible factor (HIF)-1α plays a critical role in the transcriptional activation of hypoxia inducible genes. However, the precise roles of HIF-1α independent pathways in hypoxic responses are largely unknown. Xanthine oxidase (XO) is an enzyme that utilizes molecular oxygen and produces reactive oxygen species (ROS). Here, we show that ROS derived from XO increases MMP-3, -10, and -13 expression in murine macrophages. We found that the transcript levels of macrophage MMP-3, -10, and -13 were increased in hypoxic conditions. Hypoxia induced MMP expression in HIF-1α deficient macrophages. N-acetylcysteine (NAC) or febuxostat, an XO inhibitor, suppressed MMP expression in murine macrophages. Febuxostat decreased the incidence of plaque rupture in apolipoprotein-E-deficient mice. Our results indicate that febuxostat stabilized atherosclerotic plaque via suppressing the activities of macrophage MMP-9 and -13. Febuxostat administration is a potential therapeutic option in the management of atherosclerotic patients.
DOI: 10.1172/jci117619
发表时间: 1994-12-01
影响因子: 15.9
作者:
GALIS, ZS;SUKHOVA, GK;LIBBY, P
通讯作者: LIBBY, P
DOI: 10.1038/s41598-017-15474-7
发表时间: 2017-11-09
期刊: Scientific reports
影响因子: 4.6
作者:
Azimi I;Petersen RM;Thompson EW;Roberts-Thomson SJ;Monteith GR
通讯作者: Monteith GR
DOI: 10.1038/nri3423
发表时间: 2013-05
期刊: Nature reviews. Immunology
影响因子: --
作者:
通讯作者: --
DOI: 10.1016/j.freeradbiomed.2009.11.012
发表时间: 2010-02-15
影响因子: 7.4
作者:
Kelley, Eric E.;Khoo, Nicholas K. H.;Hundley, Nicholas J.;Malik, Umair Z.;Freeman, Bruce A.;Tarpey, Margaret M.
通讯作者: Tarpey, Margaret M.
DOI: 10.1371/journal.pone.0084935
发表时间: 2014
期刊: PloS one
影响因子: 3.7
作者:
Abbas A;Aukrust P;Russell D;Krohg-Sørensen K;Almås T;Bundgaard D;Bjerkeli V;Sagen EL;Michelsen AE;Dahl TB;Holm S;Ueland T;Skjelland M;Halvorsen B
通讯作者: Halvorsen B